<DOC>
	<DOCNO>NCT02701517</DOCNO>
	<brief_summary>The primary aim study compare efficacy procedure term event-free survival patient receive cyclosporine ( CsA ) plus either alemtuzumab ( CAMPATH-1H ) methotrexate ( MTX ) match related donor allo-reduced intensity conditioning . Secondary aim : 1 . To compare incidence infection transplant-related mortality two arm ; 2. compare incidence acute chronic GVHD 3. evaluate hematologic immunologic reconstitution evolution chimerism residual disease . Patients randomly assign receive cyclosporine plus alemtuzumab cyclosporine plus MTX stratify accord diagnosis : Chronic lymphocytic leukemia Low grade- non-Hodgkin 's lymphoma . All patient receive reduced-intensity conditioning ( RIC ) scheme base fludarabine 150mg/m2 ( 30 mg/m2/day everyday -8 -4 ) plus melphalan 140mg/m2 ( 70 mg/m2/day everyday -3 -2 ) . Regarding GVHD prophylaxis , patient group 1 ( n=17 ) receive CsA 1 mg/kg intravenously start day -7 2/mg/Kg day -1 plus alemtuzumab administer dose 20 mg IV -8 -4 whereas group 2 ( n=23 ) pts receive CsA dos group 1 plus MTX give dose 15 mg/m2 intravenously day 1 10 mg/m2 day 3 , 6 11 , follow folinic acid rescue ( 15 mg +1 10 mg +3 , +6 +11 intravenously every 6 hour 4 dos start 24 hour dose MTX ) . Acute chronic GVHD similarly grade establish criterion [ 20 , 21 ] . In patient receive alemtuzumab , CsA suspend day +130 . They also receive donor lymphocyte infusion ( DLI ) dose 1 x 107 cluster differentiation 3 / kg day +180 case active disease , persistence minimal residual disease detect flow cytometry mixed chimerism GVHD . In case mixed chimerism , donor lymphocyte infusion perform patient hematopoiesis progressively increase . In patient receive CsA + MTX , CsA suspend day +180 . These patient receive DLI situation specify . The statistical analysis design identify 20 % difference term disease-free survival ( base increase incidence relapse patient receive T-cell depletion ) .</brief_summary>
	<brief_title>Cyclosporine Plus Methotrexate Alemtuzumab</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Having identical Human Leukocyte Antigens ( HLA ) mismatch family donor . 2 . Age 45 65 year ( outside age range discretion center ) . 3 . Indications : Follicular lymphoma one follow characteristic : 1 . Poor prognosis follicular NHL ( 3 factor Federico et al : erythrocyte sedimentation rate ( ESR ) &gt; 30 , male , &gt; 60 year , high LDH &gt; 2 extranodal area , pathologic stage ( PS ) &gt; 2 The International Prognostic Index ( IPI ) 3 high lactate dehydrogenase ( LDH ) micro Beta 2 ) fail achieve CR regimens include fludarabine anti CD20 ( cluster differentiation antigen 20 ) . 2 . 2nd CR ( complete response ) PR ( partial response ) candidate autologous transplantation ; 3. persistent disease relapse autologous transplantation . Other lowgrade lymphoma : 1. relapse autologous transplantation . 2. autologous transplant candidate perform inability collect sufficient number cell , steam cell disease persistence , etc.. Chronic lymphocytic leukemia one follow characteristic : 1 . `` B '' symptom : weight loss &gt; 10 % last 6 month , fever &gt; 38ÂºC ( degree centigrade ) 14 day without infection , night sweat without infection 2. lymphadenopathy &gt; 10 cm progressive , progressive splenomegaly 3 . Anemia and/or thrombocytopenia secondary bone marrow infiltration 4 . Diffuse lymphocytic infiltration bone marrow 5 . Progressive lymphocytosis ( &gt; 50 % 2 month ) lymphocyte double time &lt; 12 month Any criterion inclusion criterion protocol patient receive least one line treatment include fludarabine 6 . Patients poor prognostic cytogenetic abnormality : 17p , 11qwith VDJ unmutated 4 . Patients must also meet follow general requirement : 1 . Performance status &lt; 3 ( Zubrod score , Eastern Cooperative Oncology Group ( ECOG ) performance status WHO ( World Health Organization ) ) 2. forced expiratory volume one second ( FEV1 ) &gt; 39 % , lung diffuse capacity carbon monoxide ( DLCO ) force vital capacity ( FVC ) &gt; 39 % theoretical value 3 . Total bilirubin transaminase &lt; 3 x normal maximum value , unless attributable base haemopathy 4 . Creatinine &lt; 2 x normal maximum clearance &gt; 40 mL / min unless attributable base haemopathy 5 . No evidence symptomatic disease , cirrhosis active hepatitis 6 . Negative serology HIV 7 . Written inform consent Exclusion criterion : 1 . Impaired hepatic renal function superior describe 2 . Presence serious disease prevent chemotherapy treatment 3 . Presence psychiatric comorbidity 4 . HIV infection 5 . Other prior neoplasm 6 . Do sign inform consent 7 . Pregnant risk pregnancy inadequate contraceptive measure . 8 . Patients diagnose chronic lymphocytic leukemia ( CLL ) transformation aggressive cytologic histologic form ( prolymphocytic leukemia , large cell lymphoma , Hodgkin 's disease ) affect autoimmune hemolytic anemia</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>conditioning treatment</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>chronic lymphoproliferative disorder</keyword>
</DOC>